What's breaking now, across thousands of outlets.
Bristol Myers Squibb has ended development of a twist on the popular antibody-drug conjugate field. The Phase 1 asset that was axed is BMS-986497/ORM-6151, according to a Thursday regulatory filing from ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
The House of Representatives has called for a risk-sharing fund to attract private investment into Nigeria’s primary healthcare system, a lawmaker has said Read More…
Biggest health policy mistake in Canadian history at best, or crime against humanity at worst
An 18‑week referral‑to‑treatment target has been backed by England's former national cancer director.
Researchers are warning that inconsistent use of the terms "neurodiversity" and "neurodivergence" in mental health research could obscure important differences between diagnoses and make findings…
James sits in his room in total darkness and silence at 1:34 a.m fixing his eyes on absolutely nothing and convincing himself that he’s listening to the music playing. His family thinks he is asleep.
As alcohol licensing laws face change, new research suggests closing individual outlets can bring noticeable benefits for nearby residents.
